Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03247140
Recruitment Status : Completed
First Posted : August 11, 2017
Last Update Posted : December 26, 2017
Sponsor:
Information provided by (Responsible Party):
Jeil Pharmaceutical Co., Ltd.

Brief Summary:
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Condition or disease Intervention/treatment Phase
Hypertension With Dyslipidemia Drug: JLP-1401 Drug: Telmisartan/Amlodipine, Rosuvastatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Coadministration of Rosuvastatin and Telmisartan/Amlodipine in Healthy Adult Volunteers
Actual Study Start Date : June 10, 2017
Actual Primary Completion Date : August 7, 2017
Actual Study Completion Date : November 27, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group I (JLP-1401)
JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
Drug: JLP-1401
Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

Drug: Telmisartan/Amlodipine, Rosuvastatin
Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Experimental: Group II(Telmisartan/Amlodipine, Rosuvastatin)
Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
Drug: JLP-1401
Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

Drug: Telmisartan/Amlodipine, Rosuvastatin
Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)




Primary Outcome Measures :
  1. AUC [ Time Frame: 72hr after baseline ]
    Area under the curve of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline

  2. Cmax [ Time Frame: 72 after baseline ]
    Peak concentration of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteer, age is over 19 years Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2
  • Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
  • Subject who has the ability and willingness to participate the whole period of trial

Exclusion Criteria:

  • Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
  • Subjects who are allergic to investigational drug.
  • Subjects who have a medical history which can affect the clinical trial.
  • Systolic BP > 140mmHG or Diastolic BP > 90mmHg)
  • AST or ALT > X 2 UNL
  • History of drug abuse or positive drug screening.
  • Participation in other drug studies within 3 months prior to the drug administration.
  • Whole blood donation within 60 days, blood component donation within 30 days or who got transfusion within 30days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03247140


Locations
Layout table for location information
Korea, Republic of
Chonbuk National University Hospital
Jeonju, Korea, Republic of
Sponsors and Collaborators
Jeil Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Min Gul Kim, MD., Ph.D Chonbuk National University Hospital

Layout table for additonal information
Responsible Party: Jeil Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT03247140    
Other Study ID Numbers: JLP-1401-101-PK
First Posted: August 11, 2017    Key Record Dates
Last Update Posted: December 26, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Amlodipine
Telmisartan
Rosuvastatin Calcium
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists